Dipyridamole inhibits PDGF- and bFGF-induced vascular smooth muscle cell proliferation
- 1 December 1997
- journal article
- Published by Elsevier in Kidney International
- Vol. 52 (6), 1671-1677
- https://doi.org/10.1038/ki.1997.501
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Myointimal Hyperplasia: Pathogenesis and Implications. 2. Animal Injury Models and Mechanical FactorsArtificial Organs, 1991
- DipyridamoleNew England Journal of Medicine, 1987
- The human pharmacology of platelet inhibition: pharmacokinetics relevant to drug action.Circulation, 1985
- Inhibitors of “spontaneous” platelet aggregation in whole bloodAtherosclerosis, 1985
- Theophylline antagonizes cardiovascular responses to dipyridamole in man without affecting increases in plasma adenosineActa Physiologica Scandinavica, 1984
- Platelet‐derived growth factor is a chemoattractant for vascular smooth muscle cellsJournal of Cellular Physiology, 1982
- Aspirin and Dipyridamole Decrease Intimal Hyperplasia in Experimental Vein GraftsAnnals of Surgery, 1980
- Reduction of intimal thickening in canine coronary bypass vein grafts with dipyridamole and aspirinThe American Journal of Cardiology, 1979
- DIPYRIDAMOLE AND OTHER PHOSPHODIESTERASE INHIBITORS ACT AS ANTITHROMBOTIC AGENTS BY POTENTIATING ENDOGENOUS PROSTACYCLINThe Lancet, 1978
- Effect of Dipyridamole and Two Pyrimido-Pyrimidine Derivatives on the Kinetics of Human Platelet Aggregation and on Platelet AdhesivenessScandinavian Journal of Clinical and Laboratory Investigation, 1969